---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-011854"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2022-03-11T23:59:59+00:00"
generated_at: "2026-06-26T23:40:26.311798+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# William Lis steps down as CEO; Ronald Martell appointed President and CEO; Lis becomes Chairperson

## Summary
- William Lis terminates employment as CEO effective March 15, 2022; remains as Class III director and non-employee Chairperson for 12-month term.
- As Chairperson, Lis receives $250,000 annual fee; after board service, consulting at $12,250/month through later of 12 months or March 15, 2024.
- Lis will be granted option to purchase 100,000 shares of common stock, vesting monthly over 12 months commencing March 15, 2022.
- Prior employment agreement and severance plan terminated; if terminated without Cause, Lis receives continued annual fee and full option vesting.
- Ronald Martell appointed as President and CEO; specific compensation terms for Martell not disclosed in this filing.

## SEC filing metadata
- accession: 0001213900-22-011854
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2022-03-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390022011854/0001213900-22-011854-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390022011854/ea156711-8k_jasperther.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-011854
- JSON: https://secwatch.observer/filing/0001213900-22-011854.json
- Plain text: https://secwatch.observer/filing/0001213900-22-011854.txt

## Key facts
- Executive change
  William Lis was appointed as Chairperson of the Board at Jasper Therapeutics, Inc..
  - Action: commenced serving
  - Role: Chairperson of the Board
  source text: Mr. Lis will continue serving as a Class III director of the Company and will commence serving as a non-employee Chairperson of the Company’s Board of Directors (the “Board”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390022011854/0001213900-22-011854-index.htm
- Executive change
  Ronald Martell was appointed as President and Chief Executive Officer at Jasper Therapeutics, Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: On March 7, 2022, in connection with the appointment of Ronald Martell as the President and Chief Executive Officer of Jasper Therapeutics, Inc. (the “Company”),
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390022011854/0001213900-22-011854-index.htm
- Executive change
  William Lis was terminated as Chief Executive Officer at Jasper Therapeutics, Inc..
  - Action: terminated
  - Role: Chief Executive Officer
  source text: Mr. Lis’ employment with the Company will terminate as of March 15, 2022, at which time, Mr. Lis will continue serving as a Class III director of the Company and will commence serving as a non-employee Chairperson of the Company’s Board of Directors (the “Board”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390022011854/0001213900-22-011854-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.